Abstract
Transcatheter aortic valve implantation (TAVI) is a disruptive technology that has
dramatically changed the way clinicians care for patients with aortic stenosis. In
15 short years, this technology has progressed from first-in-human to the standard
of care for high-risk and inoperable patients with aortic stenosis. In 2016 the Canadian
Cardiovascular Society published the first ever report of quality of care for TAVI
in Canada. This report provided multiple insights into evaluating such care delivered
to Canadians and the challenges that lie ahead. In this article, we summarize these
challenges and encourage cardiologists to join the call to arms for improving quality
of TAVI care in Canada.
Résumé
Le remplacement valvulaire aortique par cathéter (TAVI) est une technologie perturbatrice
qui a changé considérablement la manière dont les cliniciens soignent les patients
atteints d'une sténose aortique. En seulement 15 ans, cette technologie est passée
de la première implantation humaine à la norme de soins chez les patients atteints
d'une sténose aortique qui sont exposés à un risque élevé et qui sont inopérables.
En 2016, la Société canadienne de cardiologie a publié le tout premier rapport sur
la qualité des soins liés au TAVI au Canada. Le présent rapport a donné de nombreux
aperçus sur l’évaluation de ces soins offerts aux Canadiens et sur les enjeux qui
se profilent à l’horizon. Dans cet article, nous faisons la synthèse de ces enjeux
et nous incitons les cardiologues à participer à l’amélioration de la qualité des
soins liés au TAVI au Canada.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Circulation. 2017; 135: e1159-e1195
- Transcatheter aortic valve replacement in Europe: adoption trends and factors influencing device utilization.J Am Coll Cardiol. 2013; 62: 210-219
- Monitoring wait times for transcatheter aortic valve implantation: a need for national benchmarks.Can J Cardiol. 2014; 30: 1150-1152
- Perioperative results and complications in 15,964 transcatheter aortic valve replacements: prospective data from the GARY registry.J Am Coll Cardiol. 2015; 65: 2173-2180
- Annual outcomes with transcatheter valve therapy: from the STS/ACC TVT registry.J Am Coll Cardiol. 2015; 66: 2813-2823
Article info
Publication history
Published online: November 22, 2017
Accepted:
November 13,
2017
Received:
August 23,
2017
Footnotes
See page 332 for disclosure information.
Identification
Copyright
© 2017 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
